Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 13 August, 2009

Curanum Ag

EANS-Adhoc: CURANUM AG / Figures Q2-2009/ HY1 2009

PR Newswire/euro adhoc/
EANS-Adhoc: CURANUM AG / Figures Q2-2009/ HY1 2009

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------

13.08.2009

Ad hoc announcement

                      Second-quarter revenue within budget

CURANUM AG, Munich, achieved revenue of EUR 64.3 million in the second quarter
of 2009. This represents an increase of 0.9% compared with the previous year's
EUR 63.7 million. The revenue included income of EUR 0.5 million from our new
senior citizens care facility of Scheffelhof in Bad Dürrheim. In addition,
occupancy in May 2009 was slightly above the previous year levels. Revenue in
the first half of 2008 totaled EUR 127.5 million, and consequently dipped
slightly by 0.1% to EUR 127.4 million.

Despite the EUR 0.4 million rise in personnel costs, operating earnings before
rental expenses (EBITDAR) were maintained at EUR 20.2 million in the second
quarter of 2009 (previous year: EUR 20.2 million), which corresponds to an
EBITDAR margin of 31.4%. Earnings before interest, tax, depreciation and
amortization (EBITDA) fell from EUR 6.8 million in the previous year to EUR 6.2
million in the second quarter of 2009 as a result of further rental indexation
adjustments. At EUR 2.4 million, depreciation and amortization in the current
reporting period was identical to that of the previous year. Earnings before
interest and tax (EBIT) fell from EUR 3.8 million (previous year: EUR 4.5
million) and earnings after tax reduced by EUR 0.6 million from EUR 1.7 million
in the second quarter of 2008 to EUR 1.1 million in the second quarter of 2009.
As a result, earnings per share (EPS) were down from EUR 0.05 to EUR 0.03 in
the second quarter of 2009 compared to the previous year.

Compared with the first half of 2008, the net financial result improved by
8.3%, from minus EUR 4.8 million as of June 30, 2009 to minus EUR 4.4 million
as of June 30, 2008. The after-tax result amounted to EUR 2.2 million (previous
year: EUR 3.8 million), and earnings per share (EPS) totaled EUR 0.07,
following EUR 0.12 in the previous year.

Cash flow from operating activities in the first half of the current financial
year amounted to EUR 8.7 million, and, despite the lower operating result, was
only slightly below cash flow in the comparable period of the previous year
(EUR 9.0 million).

As a consequence of the dividend payment, the repurchases of own shares, and
additions to earnings-neutral provisions for interest-rate hedging
transactions, equity fell from EUR 64.1 million as of December 31, 2008 by a
total of EUR 1.7 million to EUR 62.4 million at the end of the second quarter
of 2009. Consequently, the equity ratio was 26.5% (previous year: 26.7%).

For the second half of 2009, we continue to anticipate a tough competitive
environment, characterized by numerous new openings, restrictive care rate
negotiations, and the continuation of difficult financing conditions. Due to
the high supply of care facilities available for sale, accompanied by low level
of purchasing demand, we expect that purchase prices will tend to fall. In view
of this situation, we are highly confident that we will be able to exploit
attractive opportunities.

Munich, August 13, 2009

The Management Board

|Key figures IFRS as of June 30, |         |         |         |         |      
 
|2009                            |         |         |         |         |      
 
|                       |        |         |         |         |         |      
 
|mil. EUR                 |Q2 -    |Q2 - 2008|HY 1/2009|HY 1/2008|Q1 - 2009|Q1 -

2008|                       |2009    |         |         |         |         |      
 
|Sales                  |64.3    |63.7     |127.4    |127.5    |63.1     |63.7  
 
|EBITDAR                |20.2    |20.2     |40.4     |41.9     |20.2     |21.7  
 
|EBITDA                 |6.2     |6.8      |12.6     |14.7     |6.4      |7.9   
 
|Depreciation           |2.4     |2.4      |4.8      |4.7      |2.4      |2.3   
 
|EBIT                   |3.8     |4.5      |7.8      |10.0     |4.0      |5.5   
 
|Financial result       |-2.1    |-2.3     |-4.4     |-4.8     |-2.3     |-2.5  
 
|EBT                    |1.7     |2.2      |3.4      |5.3      |1.7      |3.0   
 
|Net profit             |1.1     |1.7      |2.2      |3.8      |1.1      |2.1   
 
|                       |        |         |         |         |         |      
 
|Cash Flow              |6.1     |4.9      |8.7      |9.0      |2.6      |4.1   
 
|                       |        |         |         |         |         |      
 

|                                                            
|                                                            


Further inquiry note:
Bettina Pöschl
Tel. +49(0)89-242065-69
E-Mail: [email protected]

emitter:      CURANUM AG
              Maximilianstr. 35c
              D-80539 München
phone:        +49 (0)89 242065 60
FAX:          +49 (0) 89 242065 10
mail:         [email protected]
WWW:          http://www.curanum.de
sector:       Healthcare Providers
ISIN:         DE0005240709
indexes:      SDAX, CDAX, Classic All Share, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
              Hamburg, Stuttgart, Düsseldorf, regulated dealing: München 
language:     English
        
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.

                                                                                                                                                                                                                     

a d v e r t i s e m e n t